SARS-CoV-2 - Azithromycin - Therapeutic Candidates

SARS-CoV-2 - Azithromycin - Therapeutic Candidates


Azithromycin is a macrolide antibiotic. This broad-spectrum antibiotic of the azalide group is a derivative of erythromycin. Azithromycin is indicated for the treatment of certain types of mild to moderate infections caused by bacteria. Most commonly, it is used to treat ear infections such as otitis media, throat and lung infections such as pharyngitis and pneumonia, and certain skin infections. Azithromycin is also prescribed to patients with cystic fibrosis because they are particularly susceptible to respiratory infections.
A recent study, in the context of the Covid-19 epidemic currently affecting many countries around the world, sought to investigate the effect of azithromycin in combination with hydroxychloroquine. The interest in azithromycin came from the fact that the rate of Covid-19 infection was low in a large cohort of patients with cystic fibrosis, many of whom are on azithromycin therapy.

Cat#
Description
Size
Price Excl. VAT
HY-17506-200mg
 200mg 
HY-17506-500mg
 500mg 
HY-17506-100mg
 100mg 
HY-17506-S
 0,5-1mg 
HY-17506-1mL
 10mM/1mL 
HY-17506-50mg
 50mg 
HY-17506A-50mg
 50mg 
HY-17506A-100mg
 100mg 
D288852-10mg
 10mg 
440470-1mg
 1mg 
D288852-1mg
 1mg 
440470-2,5mg
 2.5mg 
SKP3156-10
 10mg 
SKP3156-100
 100mg 
SKP3156-25
 25mg 
SKP3156-5
 5mg 
SKP3156-50
 50mg 
442033-25mg
 25mg 
442033-50mg
 50mg 
442034-1mg
 1mg 
442034-500ug
 500ug 
257209-250mg
 250mg 
Number of results per page : 10 50 250